Long-Term Opioid Efficacy Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (May 15, 2018)
Long-Term Opioid Efficacy Act of 2018
This bill expands the authority of the Food and Drug Administration (FDA)to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
What just happenedJun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Referred in SenateJun 20, 2018
- Engrossed in HouseJun 19, 2018
- Introduced in HouseMay 15, 2018
- Jun 20, 2018IntroReferral
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Jun 19, 2018FloorH38310
Motion to reconsider laid on the table Agreed to without objection.
- Jun 19, 2018FloorH37300
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243)
- Jun 19, 2018Floor8000
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5243)
- Jun 19, 2018FloorH8D000
DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.
- Jun 19, 2018FloorH30000
Considered under suspension of the rules. (consideration: CR H5243-5244)
- Jun 19, 2018FloorH30300
Mr. Walden moved to suspend the rules and pass the bill, as amended.
- May 17, 2018Committee
Ordered to be Reported (Amended) by Voice Vote.
Energy and Commerce Committee - May 17, 2018Committee
Committee Consideration and Mark-up Session Held.
Energy and Commerce Committee - May 15, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - May 15, 2018IntroReferralIntro-H
Introduced in House
- May 15, 2018IntroReferral1000
Introduced in House